Celldex Therapeutics (CLDX) EBT Margin (2010 - 2026)
Celldex Therapeutics (CLDX) posted quarterly EBT Margin of 572686.67% for Q1 2026, down 56367228.0% year-over-year from N/an in Q1 2025, and down 532.14% quarter-over-quarter from 90594.21% in Q4 2025.
Powered by 
Analysis
Celldex Therapeutics (CLDX) EBT Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' EBT Margin history runs 17 years deep, the most recent figure standing at 572686.67% for Q1 2026.
- In Q1 2026, EBT Margin fell 56367228.0% year-over-year to 572686.67%; the TTM figure through Mar 2026 stood at 37733.6% (down 3112479.0% YoY), while the FY2025 annual figure was 42819.42%, down 3601573.0% from the prior year.
- EBT Margin for Q1 2026 stood at 572686.67%, down from 90594.21% in the prior quarter.
- The five-year high for EBT Margin was 1523.91% in Q3 2024, with the low at 572686.67% in Q1 2026.
- The 5-year median for EBT Margin is 9235.98% (2023), against an average of 50767.35%.
- The sharpest annual moves came in 2025 and 2026: EBT Margin surged 1806510 bps in 2025, then sank 56367228 bps in 2026.
- Celldex Therapeutics' EBT Margin stood at 1642.1% in 2022, then tumbled by 476 bps to 9457.56% in 2023, then tumbled by 206 bps to 28982.81% in 2024, then slumped by 213 bps to 90594.21% in 2025, then slumped by 532 bps to 572686.67% in 2026.
- Business Quant data shows CLDX's EBT Margin at 572686.67% in Q1 2026, 90594.21% in Q4 2025, and 8795.07% in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 35.78% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -528.97% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 18.33% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 13.77% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 12.09% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -2.67% |
| 10 | Celldex Therapeutics | 3.10 Bn | 3.10 Bn | -2.57 Mn | -334,104.55% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -334,104.55% |
| Mar 31, 2026 | -570,260.00% |
| Dec 31, 2025 | -67,204.13% |
| Jun 30, 2025 | -7,753.42% |
| Mar 31, 2025 | -8,990.65% |
| Dec 31, 2024 | -4,007.83% |
| Sep 30, 2024 | -1,319.99% |
| Jun 30, 2024 | -1,872.74% |
| Mar 31, 2024 | -26,712.82% |
| Dec 31, 2023 | -1,048.32% |
| Sep 30, 2023 | -2,522.08% |
| Jun 30, 2023 | -12,408.96% |
| Mar 31, 2023 | -3,268.67% |
| Dec 31, 2022 | -1,642.10% |
| Sep 30, 2022 | -6,580.84% |
| Jun 30, 2022 | -22,088.34% |
| Mar 31, 2022 | -13,247.13% |
| Dec 31, 2021 | -6,032.34% |
| Sep 30, 2021 | -13,515.69% |
| Jun 30, 2021 | -384.28% |